These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 19371095

  • 1. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
    Arasappan A, Padilla AI, Jao E, Bennett F, Bogen SL, Chen KX, Pike RE, Sannigrahi M, Soares J, Venkatraman S, Vibulbhan B, Saksena AK, Girijavallabhan V, Tong X, Cheng KC, Njoroge FG.
    J Med Chem; 2009 May 14; 52(9):2806-17. PubMed ID: 19371095
    [Abstract] [Full Text] [Related]

  • 2. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
    Bogen SL, Pan W, Ruan S, Nair LG, Arasappan A, Bennett F, Chen KX, Jao E, Venkatraman S, Vibulbhan B, Liu R, Cheng KC, Guo Z, Tong X, Saksena AK, Girijavallabhan V, Njoroge FG.
    J Med Chem; 2009 Jun 25; 52(12):3679-88. PubMed ID: 19456105
    [Abstract] [Full Text] [Related]

  • 3. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan 25; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 4. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
    Venkatraman S, Blackman M, Wu W, Nair L, Arasappan A, Padilla A, Bogen S, Bennett F, Chen K, Pichardo J, Tong X, Prongay A, Cheng KC, Girijavallabhan V, George Njoroge F.
    Bioorg Med Chem; 2009 Jul 01; 17(13):4486-95. PubMed ID: 19481946
    [Abstract] [Full Text] [Related]

  • 5. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
    Di Francesco ME, Dessole G, Nizi E, Pace P, Koch U, Fiore F, Pesci S, Di Muzio J, Monteagudo E, Rowley M, Summa V.
    J Med Chem; 2009 Nov 26; 52(22):7014-28. PubMed ID: 19856919
    [Abstract] [Full Text] [Related]

  • 6. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maître C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rhéaume M, Tsantrizos YS, Lamarre D.
    J Med Chem; 2004 Mar 25; 47(7):1605-8. PubMed ID: 15027850
    [Abstract] [Full Text] [Related]

  • 7. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Venkatraman S, Velazquez F, Wu W, Blackman M, Chen KX, Bogen S, Nair L, Tong X, Chase R, Hart A, Agrawal S, Pichardo J, Prongay A, Cheng KC, Girijavallabhan V, Piwinski J, Shih NY, Njoroge FG.
    J Med Chem; 2009 Jan 22; 52(2):336-46. PubMed ID: 19102654
    [Abstract] [Full Text] [Related]

  • 8. Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
    Bogen SL, Arasappan A, Velazquez F, Blackman M, Huelgas R, Pan W, Siegel E, Nair LG, Venkatraman S, Guo Z, Doll R, Shih NY, Njoroge FG.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1854-65. PubMed ID: 20149666
    [Abstract] [Full Text] [Related]

  • 9. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
    Chen KX, Nair L, Vibulbhan B, Yang W, Arasappan A, Bogen SL, Venkatraman S, Bennett F, Pan W, Blackman ML, Padilla AI, Prongay A, Cheng KC, Tong X, Shih NY, Njoroge FG.
    J Med Chem; 2009 Mar 12; 52(5):1370-9. PubMed ID: 19196021
    [Abstract] [Full Text] [Related]

  • 10. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
    Venkatraman S, Velazquez F, Wu W, Blackman M, Madison V, Njoroge FG.
    Bioorg Med Chem Lett; 2010 Apr 01; 20(7):2151-5. PubMed ID: 20226659
    [Abstract] [Full Text] [Related]

  • 11. P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile.
    Nair LG, Sannigrahi M, Bogen S, Pinto P, Chen KX, Prongay A, Tong X, Cheng KC, Girijavallabhan V, George Njoroge F.
    Bioorg Med Chem Lett; 2010 Jan 15; 20(2):567-70. PubMed ID: 20004570
    [Abstract] [Full Text] [Related]

  • 12. Synthesis and SAR of acyclic HCV NS3 protease inhibitors with novel P4-benzoxaborole moieties.
    Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L, Kazmierski WM, Duan M, Grimes RM, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J.
    Bioorg Med Chem Lett; 2011 Apr 01; 21(7):2048-54. PubMed ID: 21353550
    [Abstract] [Full Text] [Related]

  • 13. Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
    Nair LG, Bogen S, Ruan S, Pan W, Pike R, Tong X, Cheng KC, Guo Z, Doll RJ, Njoroge FG.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1689-92. PubMed ID: 20149655
    [Abstract] [Full Text] [Related]

  • 14. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS.
    Biopolymers; 2004 Mar 01; 76(4):309-23. PubMed ID: 15386268
    [Abstract] [Full Text] [Related]

  • 15. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065
    [Abstract] [Full Text] [Related]

  • 16. Phenethyl amides as novel noncovalent inhibitors of hepatitis C virus NS3/4A protease: discovery, initial SAR, and molecular modeling.
    Colarusso S, Koch U, Gerlach B, Steinkühler C, De Francesco R, Altamura S, Matassa VG, Narjes F.
    J Med Chem; 2003 Jan 30; 46(3):345-8. PubMed ID: 12540231
    [Abstract] [Full Text] [Related]

  • 17. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
    Li X, Zhang YK, Liu Y, Zhang S, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Liu L, Bu W, Kazmierski WM, Wright LL, Smith GK, Jarvest RL, Duan M, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Ni ZJ, Zou W, Wright J.
    Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7493-7. PubMed ID: 21041080
    [Abstract] [Full Text] [Related]

  • 18. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S, Robertson K, Hernando JI, DiMuzio J, Summa V.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2295-8. PubMed ID: 19285390
    [Abstract] [Full Text] [Related]

  • 19. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.
    Perni RB, Chandorkar G, Cottrell KM, Gates CA, Lin C, Lin K, Luong YP, Maxwell JP, Murcko MA, Pitlik J, Rao G, Schairer WC, Van Drie J, Wei Y.
    Bioorg Med Chem Lett; 2007 Jun 15; 17(12):3406-11. PubMed ID: 17482818
    [Abstract] [Full Text] [Related]

  • 20. Potent aza-peptide derived inhibitors of HCV NS3 protease.
    Venkatraman S, Wu W, Shih NY, George Njoroge F.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4760-3. PubMed ID: 19596195
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.